Trial Profile
A Phase 2 Study of Abemaciclib in Patients With Recurrent Primary Brain Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- 31 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 31 Mar 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 29 Nov 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.